[go: up one dir, main page]

Matrix metalloproteinase-9 promotes neutrophil and T cell recruitment and migration in the postischemic liver

J Leukoc Biol. 2006 Jun;79(6):1295-305. doi: 10.1189/jlb.0805468. Epub 2006 Mar 21.

Abstract

Matrix metalloproteinases-2 and -9 (MMP-2/9) are critically involved in degradation of extracellular matrix, and their inhibition is discussed as a promising strategy against hepatic ischemia-reperfusion (I/R) injury. Here, we analyzed the role of MMP-2 and -9 for leukocyte migration and tissue injury in sham-operated mice and in mice after I/R, treated with a MMP-2/9 inhibitor or vehicle. Using zymography, we show that the MMP-2/9 inhibitor abolished I/R-induced MMP-9 activation, whereas MMP-2 activity was not detectable in all groups. As demonstrated by intravital microscopy, MMP-9 inhibition attenuated postischemic rolling and adherence of total leukocytes in hepatic postsinusoidal venules, CD4+ T cell accumulation in sinusoids, and neutrophil transmigration. These effects were associated with reduction of plasma tumor necrosis factor alpha (TNF-alpha) levels and endothelial expression of CD62P. Motility of interstitially migrating leukocytes was assessed by near-infrared reflected light oblique transillumination microscopy in the postischemic cremaster muscle. Upon MMP-9 blockade, leukocyte migration velocity and curve-line and straight-line migration distances were reduced significantly as compared with the vehicle-treated I/R group. Postischemic sinusoidal perfusion failure, hepatocellular apoptosis, and alanine aminotransferase activity were only slightly reduced after MMP-9 inhibition, whereas aspartate aminotransferase activity and mortality were significantly lower. In conclusion, MMP-9 is involved in the early recruitment cascades of neutrophils and CD4+ T cells, promotes neutrophil and T cell transmigration during hepatic I/R, and is required for motility of interstitially migrating leukocytes. MMP-9 blockade is associated with an attenuation of TNF-alpha release and endothelial CD62P expression, weakly protects from early microvascular/hepatocellular I/R damage, but improves postischemic survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine Transaminase / blood
  • Animals
  • Antigens, Ly / analysis
  • Apoptosis
  • Aspartate Aminotransferases / blood
  • CD4-Positive T-Lymphocytes / physiology*
  • Cell Adhesion / drug effects
  • Chemotaxis, Leukocyte / drug effects
  • Chemotaxis, Leukocyte / physiology*
  • Dipeptides / pharmacology
  • Endothelium, Vascular / pathology
  • Enzyme Activation
  • Female
  • Hepatocyte Growth Factor / biosynthesis
  • Hepatocyte Growth Factor / genetics
  • Ischemia / physiopathology*
  • Leukocyte Common Antigens / analysis
  • Liver / blood supply*
  • Liver / metabolism
  • Liver / pathology
  • Matrix Metalloproteinase 2 / physiology
  • Matrix Metalloproteinase 9 / physiology*
  • Matrix Metalloproteinase Inhibitors
  • Mice
  • Mice, Inbred C57BL
  • Muscle, Skeletal / pathology
  • Neutrophils / physiology*
  • P-Selectin / metabolism
  • Peptides, Cyclic / pharmacology
  • Protease Inhibitors / pharmacology
  • Protein Transport / drug effects
  • RNA, Messenger / biosynthesis
  • Reperfusion Injury / physiopathology*
  • Tumor Necrosis Factor-alpha / analysis
  • Venules

Substances

  • Antigens, Ly
  • CTTHWGFTLC peptide
  • Dipeptides
  • Ly6G antigen, mouse
  • Matrix Metalloproteinase Inhibitors
  • N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide
  • P-Selectin
  • Peptides, Cyclic
  • Protease Inhibitors
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Hepatocyte Growth Factor
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Leukocyte Common Antigens
  • Matrix Metalloproteinase 2
  • Matrix Metalloproteinase 9